Jundishapur Journal of Microbiology

Published by: Kowsar

Prevalence of AmpC and SHV β-Lactamases in Clinical Isolates of Escherichia coli From Tehran Hospitals

Mohammad Soltan Dallal 1 , 2 , Ailar Sabbaghi 2 , Hedrosha Molla Aghamirzaeie 2 , Abdol Rastegar Lari 3 , Mohammad Reza Eshraghian 4 , Jalil Fallah Mehrabad 5 and Zahra Rajabi 1 , *
Authors Information
1 Department of Pathobiology, Division of Microbiology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
2 Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
3 Antibiotic Resistant Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
5 Bioinformatics Institute, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2013, 6 (2); 176-180
  • Published Online: March 2, 2013
  • Article Type: Research Article
  • Received: April 8, 2012
  • Revised: May 22, 2012
  • Accepted: June 7, 2012
  • DOI: 10.5812/jjm.5043

To Cite: Soltan Dallal M, Sabbaghi A, Molla Aghamirzaeie H, Rastegar Lari A, Eshraghian M R, et al. Prevalence of AmpC and SHV β-Lactamases in Clinical Isolates of Escherichia coli From Tehran Hospitals, Jundishapur J Microbiol. 2013 ; 6(2):176-180. doi: 10.5812/jjm.5043.

Copyright © 2013, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Bakhtiari R, Fallah Mehrabadi J, Molla Agamirzaei H, Sabbaghi A, Soltan Dallal MM. 2011; 2(8)
  • 2. Rayamajhi N, Kang SG, Lee DY, Kang ML, Lee SI, Park KY, et al. Characterization of TEM-, SHV- and AmpC-type beta-lactamases from cephalosporin-resistant Enterobacteriaceae isolated from swine. Int J Food Microbiol. 2008; 124(2): 183-7[DOI][PubMed]
  • 3. Ahmed MO, Clegg PD, Williams NJ, Baptiste KE, Bennett M. Antimicrobial resistance in equine faecal Escherichia coli isolates from North West England. Ann Clin Microbiol Antimicrob. 2010; 9(12)[DOI][PubMed]
  • 4. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14(4): 933-51[PubMed]
  • 5. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18(4): 657-86[DOI][PubMed]
  • 6. Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli. Diagn Microbiol Infect Dis. 2007; 58(3): 345-8[DOI][PubMed]
  • 7. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8(3): 159-66[DOI]
  • 8. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003; 47(4): 273-95[DOI]
  • 9. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int J Antimicrob Agents. 2006; 28(6): 578-81[DOI][PubMed]
  • 10. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis. 2005; 53(4): 257-64[DOI][PubMed]
  • 11. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35(9): 1697-704[DOI]
  • 12. Performance standards for antimicrobial susceptibility testingClinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 17th informational supplement. M100-S17. 2007;
  • 13. Song W, Bae K, Lee Y-N, Lee C-H, Lee SH, Jeong SH. Detection of extended-spectrum β -lactamases by using Boronic acid as an AmpC β -lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol. 2007; 45(4): 1180-4[DOI][PubMed]
  • 14. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol. 2000; 38(5): 1791-6[PubMed]
  • 15. Al-Jasser AM. Extended-spectrum beta-lactamases (ESBLs): a global problem. Kuwait Med J. 2006; 38(3): 171-85
  • 16. Sabate M, Miro E, Navarro F, Verges C, Aliaga R, Mirelis B, et al. Beta-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother. 2002; 49(6): 989-97[DOI][PubMed]
  • 17. Kenny MJ, Birtles RJ, Day MJ, Shaw SE. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis. 2003; 9(8): 1024-5[DOI][PubMed]
  • 18. Hanson ND. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother. 2003; 52(1): 2-4[DOI][PubMed]
  • 19. Paterson DL, Ko WC, Von GA, Casellas JM, Mulazimoglu L, Klugman KP. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39(6): 2206-12[DOI][PubMed]
  • 20. Walther-Rasmussen J, Hoiby N. Plasmid-borne AmpC beta-lactamases. Can J Microbiol. 2002; 48(6): 479-93[DOI]
  • 21. Zhang Z, Guo X, Zhang Q. Prevalence characterization of extended‐spectrum β‐lactamases among Escherichia coli isolates collected in Zhengzhou. J Clin Lab analys. 2009; 23(6): 404-7[DOI][PubMed]
  • 22. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol. 2008; 46(2): 707-12[DOI][PubMed]
  • 23. Kim J, Lee HJ. Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction. Antimicrob Agents Chemother. 2000; 44(7): 18-604[DOI]
  • 24. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum- β -lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing Health Care-Associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother. 2008; 52(8): 2818-24[DOI][PubMed]
  • 25. Romero ED, Padilla TP, Hernandez AH, Grande RP, Vazquez MF, Garcia IG. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 59(4): 433-7[DOI][PubMed]
  • 26. Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M. Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian J Med Microbiol. 2007; 25(4): 346-50[DOI][PubMed]
  • 27. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001; 7(2): 333-6[DOI][PubMed]
  • 28. Jeong HS, Bae IK, Shin JH, Jung HJ, Kim SH, Lee JY, et al. Prevalence of plasmid-mediated quinolone resistance and its association with extended-spectrum beta-lactamase and AmpC beta-lactamase in Enterobacteriaceae. Korean J Lab Med. 2011; 31(4): 257-64[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments